A composition including a phosphorothioate oligonucleotide and at least one fatty acid and/or at least one emulsifying agent, where the composition is sterile and where the composition includes at least one agent including a thiol group and at least one phosphate compound, and the composition can be an ophthalmic composition. The present invention also relates to a method for obtaining the same and to the therapeutic use thereof.

A composition including a phosphorothioate oligonucleotide and at least one fatty acid and/or at least one emulsifying agent, where the composition is sterile and where the composition includes at least one agent including a thiol group and at least one phosphate compound, and the composition can be an ophthalmic composition. The present invention also relates to a method for obtaining the same and to the therapeutic use thereof.

A water-in-oil-in-water (W.sub.1/O/W.sub.2) emulsion comprising a lipid phase (O) and a water phase (W.sub.2), the lipid phase being distributed inside the water phase, wherein the lipid phase contains water droplets (W.sub.1), wherein the water content inside the lipid phase is between 10 wt % and 80 wt % relative to total weight of the lipid phase, wherein the water droplets are stabilized inside the lipid phase by an emulsifier composition, wherein the emulsifier composition comprises an Acetone-insoluble (AI) component containing a Phosphatidyl Choline (PC), a Phosphatidyl Inositol (PI), a Phosphatidyl Ethanolamine (PE) and a Phosphatidic Acid (PA), wherein PC is at most 15.5% relative to the total weight of the emulsifier composition and wherein the emulsifier composition has a phospholipid weight ratio R of at most 65%, the ratio R being defined according to Formula R(in %)=100?(PC+PI+PE+PA)/AI.

A water-in-oil-in-water (W.sub.1/O/W.sub.2) emulsion comprising a lipid phase (O) and a water phase (W.sub.2), the lipid phase being distributed inside the water phase, wherein the lipid phase contains water droplets (W.sub.1), wherein the water content inside the lipid phase is between 10 wt % and 80 wt % relative to total weight of the lipid phase, wherein the water droplets are stabilized inside the lipid phase by an emulsifier composition, wherein the emulsifier composition comprises an Acetone-insoluble (AI) component containing a Phosphatidyl Choline (PC), a Phosphatidyl Inositol (PI), a Phosphatidyl Ethanolamine (PE) and a Phosphatidic Acid (PA), wherein PC is at most 15.5% relative to the total weight of the emulsifier composition and wherein the emulsifier composition has a phospholipid weight ratio R of at most 65%, the ratio R being defined according to Formula R(in %)=100?(PC+PI+PE+PA)/AI.

Provided herein are methods of treating non-hemorrhagic closed head injury (NHCHI) with 3,3-diindolylmethane or an analog thereof. In one embodiment, NHCHI covers Traumatic Brain Injuries (TBIs) including mild to severe concussion, blast injury due to proximity to explosions, cerebral contusion, coup-contrecoup injury, DAI, Second Impact Syndrome, or CHI associated with deceleration injury.

The present invention discloses a novel local anesthetic analgesic sustained-release drug delivery system. The system includes an internal aqueous phase, an external aqueous phase, an oil phase, an organic solvent, an isoosmotic regulator and a pH regulator. The internal aqueous phase includes an analgesic, a drug solvent and a drug solubilizer. The analgesic is selected from one of bupivacaine, levobupivacaine, ropivacaine, lidocaine and tetracaine, and the analgesic is in a free base form or an acid saline form; the drug solvent is selected from inorganic acid containing N or P; and the drug solubilizer is selected from one or more of saccharide and ring-shaped organic acid. The multivesicular liposome prepared in the present invention has the advantages of high encapsulation percentage and drug loading capacity, uniform grain size, and good sustained-release effect.

A system and method that uses receptor-targeted microbubbles to locate abnormal cell tissue for therapy is disclosed. The method includes applying receptor-targeted microbubbles to abnormal cell tissue; imaging the applied microbubbles using an imaging system; and locating the abnormal cell tissue using the imaged, applied microbubbles, wherein the imaging system detects and 5 transmits imaging information of the applied microbubbles through a gaseous environment, i.e., a non-contact procedure. Embodiments of the system and method combine the targeting of microbubbles to abnormal cell tissue and an imaging system, the combination of which is capable of accurately and rapidly assessing the surgical margin for presence of unseen cancer in, for example, the operating room, at bedside, or in an 10 office, within or outside the body.

A system and method that uses receptor-targeted microbubbles to locate abnormal cell tissue for therapy is disclosed. The method includes applying receptor-targeted microbubbles to abnormal cell tissue; imaging the applied microbubbles using an imaging system; and locating the abnormal cell tissue using the imaged, applied microbubbles, wherein the imaging system detects and 5 transmits imaging information of the applied microbubbles through a gaseous environment, i.e., a non-contact procedure. Embodiments of the system and method combine the targeting of microbubbles to abnormal cell tissue and an imaging system, the combination of which is capable of accurately and rapidly assessing the surgical margin for presence of unseen cancer in, for example, the operating room, at bedside, or in an 10 office, within or outside the body.

The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.